A Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Trial Profile

A Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs ABT 957 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 14 Jun 2016 Status changed from recruiting to discontinued.
    • 08 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Jun 2016, as reported by ClinicalTrials.gov.
    • 08 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top